GB1554157A - Stable insulin preparation for intra nasal administration - Google Patents

Stable insulin preparation for intra nasal administration

Info

Publication number
GB1554157A
GB1554157A GB2535175A GB2535175A GB1554157A GB 1554157 A GB1554157 A GB 1554157A GB 2535175 A GB2535175 A GB 2535175A GB 2535175 A GB2535175 A GB 2535175A GB 1554157 A GB1554157 A GB 1554157A
Authority
GB
United Kingdom
Prior art keywords
nasal administration
insulin preparation
stable insulin
intra nasal
intra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2535175A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to GB2535175A priority Critical patent/GB1554157A/en
Priority to DE19762620483 priority patent/DE2620483A1/de
Priority to JP5493176A priority patent/JPS51148013A/ja
Priority to FR7614706A priority patent/FR2313914A1/fr
Priority to BE167069A priority patent/BE841870A/xx
Priority to US05/824,955 priority patent/US4153689A/en
Publication of GB1554157A publication Critical patent/GB1554157A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB2535175A 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration Expired GB1554157A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB2535175A GB1554157A (en) 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration
DE19762620483 DE2620483A1 (de) 1975-06-13 1976-05-08 Stabile waessrige insulinloesungen
JP5493176A JPS51148013A (en) 1975-06-13 1976-05-13 Stable insulin preparation for nosal administration
FR7614706A FR2313914A1 (fr) 1975-06-13 1976-05-14 Preparation stable a base d'insuline pour une administration nasale
BE167069A BE841870A (fr) 1975-06-13 1976-05-14 Preparation stable d'insuline
US05/824,955 US4153689A (en) 1975-06-13 1977-08-15 Stable insulin preparation for nasal administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2535175A GB1554157A (en) 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration

Publications (1)

Publication Number Publication Date
GB1554157A true GB1554157A (en) 1979-10-17

Family

ID=10226264

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2535175A Expired GB1554157A (en) 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration

Country Status (5)

Country Link
JP (1) JPS51148013A (enrdf_load_stackoverflow)
BE (1) BE841870A (enrdf_load_stackoverflow)
DE (1) DE2620483A1 (enrdf_load_stackoverflow)
FR (1) FR2313914A1 (enrdf_load_stackoverflow)
GB (1) GB1554157A (enrdf_load_stackoverflow)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US5053389A (en) * 1986-04-18 1991-10-01 Per Balschmidt Insulin preparation for non-parenteral administration
EP0351651B1 (en) * 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
US5693608A (en) * 1990-05-10 1997-12-02 Bechgaard International Research And Development A/S Method of administering a biologically active substance
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064888D1 (en) * 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
DE2917535C2 (de) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Gegen Denaturierung beständige Insulinlösungen
WO1983000288A1 (en) * 1981-07-17 1983-02-03 Balschmidt, Per A stable aqueous, therapeutic insulin preparation and a process for preparing it
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
CA1274774A (en) * 1985-04-15 1990-10-02 Kenneth S. Su Method for administering insulin
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
CZ288146B6 (en) 1994-12-22 2001-05-16 Astra Ab Pharmaceutical aerosol preparation, process of its preparation and use
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
DE602004028284D1 (de) * 2003-12-08 2010-09-02 Cpex Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
US7851419B2 (en) * 2005-09-12 2010-12-14 Nawaz Ahmad Substantially anhydrous sprayable personal lubricant
ITRM20110390A1 (it) 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
EP3030294B1 (en) * 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62232C (enrdf_load_stackoverflow) * 1900-01-01
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US5053389A (en) * 1986-04-18 1991-10-01 Per Balschmidt Insulin preparation for non-parenteral administration
EP0351651B1 (en) * 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
US5693608A (en) * 1990-05-10 1997-12-02 Bechgaard International Research And Development A/S Method of administering a biologically active substance
AU687496B2 (en) * 1990-05-10 1998-02-26 Lyfjathroun HF., Biopharmaceuticals (Lyfjaproun) Nasal administration
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US12303598B2 (en) 2009-11-13 2025-05-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US12186374B2 (en) 2014-12-12 2025-01-07 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
DE2620483A1 (de) 1976-12-23
FR2313914B1 (enrdf_load_stackoverflow) 1979-04-13
JPS51148013A (en) 1976-12-18
FR2313914A1 (fr) 1977-01-07
BE841870A (fr) 1976-11-16

Similar Documents

Publication Publication Date Title
GB1554157A (en) Stable insulin preparation for intra nasal administration
NZ179733A (en) Stable insulin preparation
FR2321275A1 (fr) Preparation d'insuline pour administration nasale
GB1540881A (en) Medicament infuser units
PH23643A (en) Nasal pharmaceutical composition
GR58257B (en) Novel pharmaceutical preparation adapted for oral administration
GB2014953B (en) Intravenous administration set
PH12959A (en) Preparation of pharmaceutical unit dosage form
CS187429B2 (en) Inhalator for administering the powder medicines
JPS5210415A (en) Anodyne for intraintestinal administration and its preparation
NZ179725A (en) Medicament dispensing inhalation device
NZ194047A (en) Medicinal preparations for the parenteral administration of fat-soluable medicaments
NZ184060A (en) Sprayable pharmaceutical composition for topical administration
IL58209A0 (en) Medicament inhaler
ZA764868B (en) Novel pharmaceutical preparation adapted for oral administration
NZ180321A (en) Sustained release pharmaceutical preparation
GB1539076A (en) Process for preparing preparations for oral administration
IL51096A0 (en) Novel pharmaceutical dosage form
AU1609576A (en) Anesthetic delivery system
GB2014952B (en) Metering apparatus especially for use with an intravenous solution administration set
GB1549171A (en) Pharmaceutical formulations containing hydrocy bezophenonederivatives
GB2001076B (en) Psychopharmacological peptides suitable for therapeutic administration
AU1306576A (en) Pharmaceutical formulation
AU8397675A (en) Insulin, analogs and derivatives thereof
JPS51133429A (en) Anesthetic composition

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee